S

    Sutro Biopharma (STRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $20.45
    -0.86 (-4.04%)

    Market Cap: $339.08M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(16/32)
    Avg Surprise
    -133.74%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-2.64
    Range$-2.86 - $-2.42
    2 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$0.00+100.0%
    7d ago$-2.42+8.3%
    Current$-2.64
    Revenue Consensus
    $8M
    Range$0 - $15M
    13 analysts
    Dec 31, 2026
    EPS Consensus$0.38
    Range$-2.17 - $1.75
    3 analysts
    Revenue Consensus
    $25M
    Range$3M - $98M
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.38---
    Sep 26EST
    		-$-2.64---
    Jun 26
    		$-2.33$-2.04-14.22%Miss-1564.3%
    Mar 26
    		$-2.94$-3.21+8.41%Beat+63.3%
    Dec 25
    		$-5.45$-0.43-1152.85%Miss-760.3%
    Sep 25
    		$-5.57$-3.55-56.90%Miss-11.8%
    Jun 25
    		$-0.14N/A+64.10%Beat+97.5%
    Mar 25
    		$-8.02$-9.20+12.83%Beat+9.9%
    Dec 24
    		$-0.63$-0.95+33.70%Beat-221.8%
    Sep 24
    		$-4.98$-7.35+32.24%Beat+38.5%
    Jun 24
    		$-5.61$-9.00+37.67%Beat+27.0%
    Mar 24
    		$-8.90$-9.95+10.55%Beat-947.1%
    Dec 23
    		$0.52$-0.82+163.41%Beat+106.4%
    Sep 23
    		$-8.10$-7.15-13.29%Miss-118.9%
    Jun 23
    		$-7.69$-6.87-11.94%Miss-39.8%
    Mar 23
    		$-0.85$-0.81-4.94%Miss+89.9%
    Dec 22
    		$-8.18$-6.32-29.43%Miss-885.5%
    Sep 22
    		$-3.70$0.12-3183.33%Miss+44.8%
    Jun 22
    		$-5.50$-7.70+28.57%Beat-323.1%
    Mar 22
    		$-8.40$-7.37-13.98%Miss-96.3%
    Dec 21
    		$-0.83$-0.69-20.29%Miss+43.9%
    Sep 21
    		$-6.70$-4.80-39.58%Miss-100.6%
    Jun 21
    		$-1.30N/A+67.50%Beat+78.2%
    Mar 21
    		$-4.28$-6.00+28.67%Beat+49.0%
    Dec 20
    		$-1.48$-0.57-159.65%Miss-131.3%
    Sep 20
    		$-3.34$-5.00+33.20%Beat+40.4%
    Jun 20
    		$-5.97$-5.74-4.01%Miss+0.5%
    Mar 20
    		$-8.40$-5.68-47.89%Miss-35.5%
    Dec 19
    		$-0.64$-0.69+7.25%Beat-146.2%
    Sep 19
    		$-5.60$-6.17+9.24%Beat-29.0%
    Jun 19
    		$-6.00$-6.01+0.17%Beat-338.0%
    Mar 19
    		$-6.20$-6.10-1.64%Miss-
    Dec 18
    		$-0.26N/A+58.73%Beat-
    Sep 18
    		$-4.34N/A-122.03%Miss-
    Jun 18
    		$-1.37$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.26EV/EBITDA41.71x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-301.70%
    ROE-1810.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-3.51x
    Current Ratio3.32xQuick Ratio3.32x
    Trading Statistics
    Beta1.51Avg Volume272.13K
    52-Week High$43.8552-Week Low$7.15

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$21.36
    SMA 20$22.63
    SMA 50$25.55
    SMA 200$21.96
    EMA 10$21.42
    EMA 20$22.32
    EMA 50$24.53
    EMA 200$22.67

    MACD

    Line: -1.26Signal: -1.28Hist: 0.02

    ADX

    ADX: 35.7+DI: 10.9-DI: 32.3

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down52.0
    PSAR$24.63

    Bollinger Bands

    Upper Band$26.56
    Lower Band$18.70
    %B Position3471%(Upper)
    Band Width0.22

    RSI (14-Day)

    Neutral
    36.9

    Momentum Oscillators

    Stoch %K34.5
    Stoch %D35.8
    Williams %R-72.3
    ROC (10d)-0.1%
    Momentum-0.03
    CCI (20d)-71.9
    MFI (14d)40.4

    Volatility Measures

    ATR (14d)$1.75(8.6%)
    StdDev (20d)1.96
    Hist Vol75.8%(High)

    Volume Flow

    VWAP$20.76
    OBV-18.5M
    AD Line37.8B
    CMF (20d)-0.011

    Volume Metrics

    Avg Vol (20d)283.8K
    Vol Ratio0.5x
    VWMA (20d)$22.02

    Pivot Points

    R3$22.29
    R2$21.98
    R1$21.65
    Pivot Point$21.34
    S1$21.01
    S2$20.70
    S3$20.37

    Advanced Oscillators

    TSI-21.79
    Ultimate Osc44.1
    KST-162.98

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$9.84M$14.52M$11.65M$9.69M$63.74M$17.40M$14.81M$8.52M$25.71M$13.01M$113.72M$16.92M
    Cost of Revenue$0$0$1.62M$0$0$0$-1,738,000$0$0$0$1.73M$0
    Gross Profit$9.84M$14.52M$11.65M$9.69M$63.74M$17.40M$14.81M$8.52M$25.71M$13.01M$113.72M$16.92M
    Operating Expenses$39.73M$44.18M$49.70M$58.15M$67.09M$85.91M$80.07M$76.44M$74.39M$69.60M$70.57M$60.94M
    R&D$31.70M$36.55M$36.64M$39.85M$38.33M$51.60M$71.04M$62.11M$62.02M$56.88M$53.77M$45.67M
    SG&A$7.83M$7.58M$8.66M$8.74M$10.34M$13.27M$9.03M$14.33M$12.37M$12.72M$16.80M$15.27M
    Operating Income$-29,888,000$-29,656,000$-38,049,000$-48,459,000$-3,345,000$-68,514,000$-65,258,000$-67,919,000$-48,685,000$-56,591,000$43.15M$-44,014,000
    Interest Income$1.72M$1.64M$1.53M$2.01M$2.52M$3.19M$4.76M$4.88M$4.91M$4.10M$4.56M$4.55M
    Interest Expense$10.37M$10.48M$10.32M$10.41M$10.69M$10.64M$1.10M$-14,257,000$9.04M$9.40M$8.73M$8.68M
    Income Before Tax$-38,532,000$-38,499,000$-46,837,000$-56,857,000$-11,517,000$-75,961,000$-70,088,000$-48,787,000$-48,010,000$-58,213,000$46.87M$-47,445,000
    Income Tax Expense$1,000$-15,000$0$0$-18,000$7,000$0$0$8,000$0$15.81M$1.84M
    Net Income$-38,533,000$-38,484,000$-46,762,000$-56,857,000$-11,499,000$-75,968,000$-72,443,000$-48,787,000$-48,018,000$-58,213,000$31.07M$-49,284,000
    EBITDA$-29,079,000$-28,823,000$-36,956,000$-47,314,000$-2,478,000$-67,730,000$-64,929,000$-68,817,000$-44,914,000$-53,807,000$49.72M$-43,975,000
    EBIT$-29,888,000$-29,656,000$-38,049,000$-48,459,000$-3,345,000$-68,514,000$-65,258,000$-67,919,000$-43,877,000$-52,912,000$51.05M$-43,320,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about STRO

    News

    A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $49 to $56

    Five major Wall Street analysts have updated their ratings for Sutro Biopharma (STRO.US), all maintaining a buy rating. The price targets for STRO.US range from $49 to $56. One analyst, Wells Fargo's Eva Fortea Verdejo, adjusted her target price upwards from $27 to $49.

    Moomoo•8/21/26•
    Bullish

    Stifel Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $48

    Stifel has reiterated its Buy rating for Sutro Biopharma (STRO.US) and maintained its price target of $48. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

    Moomoo•8/17/26•
    Bullish

    Broker Revenue Forecasts For Sutro Biopharma, Inc. (NASDAQ:STRO) Are Surging Higher

    Sutro Biopharma, Inc. (NASDAQ:STRO) has received significant upgrades to its 2026 revenue and loss forecasts from analysts, with expected revenues increasing to US$51m and losses shrinking to US$8.34 per share. Despite these positive adjustments, the analysts' price target of US$47.23 remains unchanged. The company's projected annual growth of 25% for 2026 is anticipated to align with the broader industry's growth rate.

    Simply Wall Street•8/17/26•
    Somewhat-Bullish

    Sutro Biopharma, Inc. (NASDAQ:STRO) Just Reported And Analysts Have Been Lifting Their Price Targets

    Sutro Biopharma (NASDAQ: STRO) reported revenues of US$9.8m, missing analyst expectations, while statutory losses per share were US$2.33. Analysts now forecast 2026 revenues of US$44.4m and losses of US$8.73 per share, with the average price target falling 5.4% to US$50.33. Despite the lowered price target, analysts largely reconfirmed revenue and loss estimates, suggesting intrinsic value could improve, but the company's revenue growth is expected to lag the wider industry.

    Sahm•8/15/26•
    Somewhat-Bearish

    Sutro Biopharma, Inc. (NASDAQ:STRO) Just Reported And Analysts Have Been Lifting Their Price Targets

    Sutro Biopharma, Inc. (NASDAQ:STRO) recently reported quarterly results that fell short of analyst expectations, with revenues missing by 11% and statutory losses per share slightly higher than predicted. Despite this, analysts have reconfirmed their revenue estimates for 2026 and upgraded the average price target to US$50.33, suggesting a belief in the company's intrinsic value improving over time. However, the company's revenue is still expected to decline and underperform the wider industry.

    Simply Wall Street•8/15/26•
    Somewhat-Bearish

    Frequently Asked Questions About STRO

    Does STRO pay dividends?
    Sutro Biopharma (STRO) does not currently pay a regular dividend.
    What is STRO's market cap?
    Sutro Biopharma (STRO) has a market capitalization of $339.08M with a current stock price of $20.45.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In